Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Overview of attention for article published in PharmacoEconomics, February 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source
twitter: 1 X user

facebook: 1 Facebook page

Readers on

mendeley: 87 Mendeley

Summary Policy documents X Facebook

So far, Altmetric has seen 1 public wall post.

Healtheconbot, 26 Feb 2018

#HealthEconJA Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE…